Intravitreal injection of bevacizumab in Eales disease.
To report a case of presumed Eales disease that showed regression of retinal neovascularization after the use of intravitreal bevacizumab. Retrospective, interventional case report. Broad retinal neovascularization in a patient with presumed Eales disease did not regressed despite adequate photocoagulation treatment, and bevacizumab (1.25 mg) was injected intravitreally. The patient was followed up for 1 year. One week after injection, fluorescein angiography demonstrated dramatic regression of retinal neovascularization. After 12-months, visual acuity was improved and no signs of recurrence were observed. Intravitreal bevacizumab may be effective as an adjunctive treatment of retinal neovascularization in patients with Eales disease.